Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of nab-paclitaxel as neoadjuvant therapy in stage II–III luminal breast cancer
2011-004476-10Phase 2Completed
- Sponsor
- GEICAM
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in breast cancer, sponsored by GEICAM. Primary endpoints: Residual cancer burden grade III (RCB-III) rate and Residual cancer burden 0/I (RCB-0/1) rate. Started Nov 2011; status: completed.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-004476-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004476-10.